Please assess the completion status of the following clinical trial:

Trial Title: Ranolazine and Pulmonary Hypertension

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~1. World Health Organization (WHO) Group 1 PAH, defined as a pulmonary hypertension with mean pulmonary artery pressure \> 25 mmHg, pulmonary capillary wedge pressure \< 15 mmHg, and pulmonary vascular resistance \> 3 Wood units.~2. Right ventricular dysfunction, defined as RV fractional area change \< 32% or RV tricuspid annular plane systolic excursion (TAPSE) \< 15 mm.~3. Symptoms of angina or angina equivalent (exertional dyspnea, exertional epigastric pain, exertional nausea).~4. New York Heart Association functional class II or III symptoms.~5. Stable doses of pulmonary vasodilators (prostacyclins, endothelin receptor antagonists, phosphodiesterase inhibitors), with no new therapy initiation or dose escalation \> 50% in the 4 weeks prior to randomization.~6. Age 18-80 years.~Exclusion criteria:~1. Acute coronary syndrome or coronary revascularization within the prior 3 months.~2. Patients with unstable angina.~3. Patients with Class IV congestive heart failure.~4. Planned revascularization, pacemaker or defibrillator placement during the study period.~5. Changes in antianginal medical therapy likely to occur during the study period.~6. Corrected QT interval measurement \>500 ms.~7. Patients with pre-existing QT prolongation (including congenital long QT syndrome) or receiving other QT prolonging drugs (including Class Ia-e.g., quinidine, Class III-e.g., dofetilide, sotalol, antiarrhythmics; antipsychotics (e.g., thioridazine, ziprasidone), or known history of complex ventricular arrhythmias requiring antiarrhythmic medications or ICD implantation.~8. Patients with known history of hepatic dysfunction.~9. Current use of strong CYP3A inhibitors, including ketoconazole, itraconazole, clarithromycin, nefazodone, nelfinavir, ritonavir, indinavir, saquinavir and diltizaem.~10. Patients with pacemakers, cochlear implants, aneurysm clips, who have worked with metal.~11. Patients with metallic hardware, implants, or prostheses will consult with the radiologist/cardiologist prior to the study.~12. Patients with severe or end stage renal disease (an estimated GFR \< 30 mL/min/1.73 m).~13. Women who are pregnant or lactating~14. Any contraindications for the use of a right heart catheter including, but not limited to:~    * Pulmonic or tricuspid valve stenosis~   * Prosthetic pulmonic or tricuspid valve~   * Right atrial or ventricular masses~   * Previous pneumonectomy~   * Risk of severe arrhythmias, including left bundle branch block (LBBB)~15. Subjects unable to perform cardiopulmonary exercise testing will be excluded (i.e. extensive musculoskeletal disease)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Ranolazine (Type: EXPERIMENTAL): 1000 mg PO BID

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete